Boundless Bio (United States)

company in San Diego, United States

BOLD Nasdaq SEC CIK 1782303
Follow Boundless Bio (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$5.4M +61.4% vs same quarter last year
EPS, diluted −$0.23 +62.9% vs same quarter last year
Operating cash flow −$10.9M −6.7% vs same quarter last year
Operating income −$6.2M +59.1% vs same quarter last year
Net income by quarter
−$16.4M
−$15.8M
−$15.7M
−$13.9M
−$12.9M
−$13.6M
−$23.7M
−$5.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$80M−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$58.2M
FY24−$65.4M
FY23−$49.4M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$47.2M
FY24−$63.4M
FY23−$47.5M
FY22-